NasdaqGS - Nasdaq Real Time Price • USD
Aclaris Therapeutics, Inc. (ACRS)
At close: May 28 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.2 | -0.18 | -0.8 | -0.63 |
| Low Estimate | -0.34 | -0.31 | -1.21 | -1.35 |
| High Estimate | -0.12 | -0.1 | -0.53 | -0.4 |
| Year Ago EPS | -0.42 | -0.41 | -1.27 | -0.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 8 | 8 |
| Avg. Estimate | 1.82M | 1.83M | 7.89M | 7.74M |
| Low Estimate | 660k | 660k | 4.37M | 2.63M |
| High Estimate | 2.5M | 2.6M | 10.19M | 12.19M |
| Year Ago Sales | 1.9M | -- | 31.25M | 7.89M |
| Sales Growth (year/est) | -4.20% | -- | -74.80% | -1.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.45 | -0.48 | -0.34 | -0.29 |
| EPS Actual | -0.42 | -0.41 | -0.02 | -0.24 |
| Difference | 0.03 | 0.07 | 0.32 | 0.05 |
| Surprise % | 6.70% | 14.60% | 94.10% | 17.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.18 | -0.8 | -0.63 |
| 7 Days Ago | -0.2 | -0.18 | -0.8 | -0.63 |
| 30 Days Ago | -0.25 | -0.23 | -0.99 | -0.82 |
| 60 Days Ago | -0.25 | -0.23 | -0.99 | -0.82 |
| 90 Days Ago | -0.27 | -0.25 | -1.16 | -1.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 7 | 6 | 8 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACRS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 52.40% | -- | -- | 7.90% |
| Next Qtr. | 56.10% | -- | -- | 10.20% |
| Current Year | 37.00% | -- | -- | 4.80% |
| Next Year | 21.30% | -- | -- | 12.50% |
| Next 5 Years (per annum) | 74.40% | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 1/22/2024 |
| Downgrade | BTIG: Buy to Neutral | 1/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/29/2023 |
| Maintains | Stifel: Hold to Hold | 12/18/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/14/2023 |
| Downgrade | Cantor Fitzgerald: Overweight to Neutral | 11/14/2023 |
Related Tickers
MYNZ Mainz Biomed N.V.
0.7600
+34.49%
ENZ Enzo Biochem, Inc.
1.1800
+10.28%
CNTG Centogene N.V.
0.3898
+4.22%
PSNL Personalis, Inc.
1.2900
-3.73%
CDNA CareDx, Inc
16.15
+1.32%
TELO.V Telo Genomics Corp.
0.1800
0.00%
SERA Sera Prognostics, Inc.
8.61
-0.46%
STRR Star Equity Holdings, Inc.
0.8900
-2.11%
CBAV.MC Clínica Baviera, S.A.
29.20
0.00%
NDRA ENDRA Life Sciences Inc.
0.2748
-2.62%